Clinical suspicion, pharmacovigilance, and pharmacogenetics in the prevention of severe outcomes of febrile neutropenia
Introduction. Febrile neutropenia (FN) is one of the most clinically significant and potentially life-threatening complications of anticancer drug therapy (ADT), requiring timely recognition and the immediate treatment initiation. This problem is of particular importance for primary care physicians, as the onset of fever in a patient currently receiving – or having recently completed – ADT may be the first and only one manifestation of a severe infectious process occurring in connection with neutropenia.E.I. Busalaeva, S.M. Zhuchkova, G.A. Gromova
Objective: To examine the structure and outcomes of documented FN cases in real clinical practice, and to substantiate the importance of clinical suspicion among primary care physicians, as well as the relevance of pharmacovigilance and pharmacogenetic testing in preventing severe ADT complications.
Material and methods. Data from real clinical practice at the Republican oncology dispensaries of the Republic of Karelia and the Republic of Chuvashia (2019–2025) were analyzed regarding the detection and registration of FN cases. Clinical examples are provided to illustrate the onset of this medical emergency condition within the oncology service.
Results. A total of 149 cases of FN were recorded across these medical institutions, 35 (23.5%) of which were fatal. FN episodes occurred in cases with various primary tumor sites and across a wide range of anticancer treatment regimens, underscoring the need for systematic risk assessment for this complication, regardless of the specific treatment protocol. An analysis of the recorded cases indicates that non-oncologist physicians are insufficiently involved in identifying and reporting FN cases to the pharmacovigilance system. Using a clinical case of severe myelotoxicity associated with an irinotecan-based regimen as an example, the potential for pharmacogenetic testing – specifically for UGT1A1 gene polymorphisms – is discussed as a tool for personalized risk assessment of severe neutropenia arising.
Conclusion. Increasing awareness of FN among primary-contact physicians, developing active pharmacovigilance, ensuring the rational use of granulocyte colony-stimulating factors, and implementing personalized risk assessment approaches can help improve the safety of anticancer therapy and prevent severe outcomes associated with febrile neutropenia.
Keywords
References
- Сакаева Д.Д., Борисов К.Е., Булавина И.С., Когония Л.М., Курмуков И.А., Орлова Р.В., Шабаева М.М. Фебрильная нейтропения. Злокачественные опухоли. 2025;15(3s2–2):64–73. [Sakaeva DD, Borisov KE, Bulavina IS, Kogonia LM, Kurmukov IA, Orlova RV, Shabaeva MM. Febrile neutropenia. Zlokachestvennyye opukholi = Malignant Tumors. 2025;15(3s2–2):64–73 (In Russ.)].
EDN: TDGPNG. https://doi.org/10.18027/2224-5057-2025-15-3s2-2-04
- Горбунова В.А., Стенина М.Б., Алиев Т.З.О., Артамонова Е.В., Архири П.П., Бабичева Л.Г. с соавт. Противоопухолевая лекарственная терапия. Национальное руководство. М.: ГЭОТАР-Медиа. 2022; с. 624–638. [Gorbunova VA, Stenina MB, Aliev TZO, Artamonova EV, Arkhiri PP, Babicheva LG, et al. Antitumor drug therapy. National guide. Moscow: GEOTAR-Media. 2022; 624–638 pp. (In Russ.)].
ISBN: 978-5-9704-6897-5. https://doi.org/10.33029/9704-6897-5-ATDT-2022-1-708
- Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et. al. The Multinational Association for Supportive Care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.
PMID: 10944139. https://doi.org/10.1200/JCO.2000.18.16.3038
- Сапожников К.В., Сорокина И.В., Гусев А.В., Саблева Н.А., Соколова В.Д., Толкачева Д.Г., Березина А.М. Профилактика фебрильной нейтропении у онкологических пациентов: данные реальной клинической практики. Современная онкология. 2023;25(1):115–122. [Sapozhnikov KV, Sorokina IV, Gusev AV, Sableva NA, Sokolova VD, Tolkacheva DG, Berezina AM. Prevention of febrile neutropenia in oncological patients: Real-world data. Sovremennaya onkologiya = Journal of Modern Oncology. 2023;25(1):115–122 (In Russ.)].
EDN: QPQHVZ. https://doi.org/10.26442/18151434.2023.1.202138
- Мухаммадиев С.Б., Асилов С.С., Олимжонов К.А., Махамадалиева Г.З., Каюмов А.А., Исхаков Э.Д., Дроков М.Ю. Предварительные результаты эскалационной стратегии антибактериальной терапии у пациентов после аллогенной трансплантации гемопоэтических стволовых клеток в ранний посттрансплантационный период: ретроспективное исследование одного центра. Онкогематология. 2026;21(2):105–115. [Mukhammadiev SB, Asilov SS, Olimzhonov KA, Makhamadalieva GZ, Kayumov AA, Iskhakov ED, Drokov MYu. Preliminary results of an escalation strategy of antibacterial therapy in patients after allogeneic hematopoietic stem cell transplantation in the early post transplantation period: A single center retrospective study. Onkogematologiya = Oncohematology. 2026;21(2):105–115 (In Russ.)].
EDN: PNPZNR. https://doi.org/10.17650/1818-8346-2026-21-2-105-115
- Громова Г.А. Реальная клиническая практика профилактики и лечения нейтропении: как повысить качество онкологической помощи и сэкономить? Опухоли женской репродуктивной системы. 2023;19(2):69–81. [Gromova GA. Real world clinical practice of neutropenia prevention and treatment: How to improve the quality of oncological care and save money? Opukholi zhenskoy reproduktivnoy sistemy = Tumors of the Female Reproductive System. 2023;19(2):69–81 (In Russ.)].
EDN: AEMPHY. https://doi.org/10.17650/1994-4098-2023-19-2-69-81
- Жучкова С.М., Бусалаева Е.И., Вазанов А.А. Фебрильная нейтропения как нежелательное событие противоопухолевой лекарственной терапии. Пациент. Врач. Лекарство. Сборник научных материалов. Казань: ИД «МеДДоК». 2023: с. 77–80. [Zhuchkova SM, Busalaeva EI, Vazanov AA. Febrile neutropenia as an adverse event of anticancer drug therapy. Patient. Doctor. Medicine. Collection of scientific materials. Kazan: MeDDok Publishing House. 2023: 77–80 pp. (In Russ.)].
EDN: CTSMNB. ISBN: 978-5-907551-95-4.
- Кононенко И.Б., Снеговой А.В., Ларионова В.Б. Нейтропения, лимитирующая проведение химиотерапии. Нужна ли профилактика? Онкогематология. 2022;17(1):135–142. [Kononenko IB, Snegovoy AV, Larionova VB. Neutropenia limiting chemotherapy. Is prevention needed? Onkogematologiya = Oncohematology. 2022;17(1):135–142 (In Russ.)].
EDN: XGCOST. https://doi.org/10.17650/1818-8346-2022-17-1-135-142
- Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, et al. WBC growth factors: ASCO guideline update. J Clin Oncol. 2026;44(9):812–24.
PMID: 41740078. https://doi.org/10.1200/JCO-25-02938
- Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, et al. Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan. J Clin Oncol. 2021;39(15 suppl):3574.
https://doi.org/10.1200/JCO.2021.39.15_suppl.3574
- Nguyen CTT, Nguyen TMT, Phung TH. Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients. Pharmacogenomics. 2024;25(10–11):469–77.
PMID: 39171626. PMCID: PMC11492647. https://doi.org/10.1080/14622416.2024.2385289
- Клинические рекомендации. Рак прямой кишки. Общероссийская общественная организация «Ассоциация колопроктологов России», Ассоциация онкологов России, Общероссийская общественная организация «Российское общество клинической онкологии», Российское общество специалистов по колоректальному раку. Рубрикатор клинических рекомендаций Минздрава России. 2025. ID: 554_4. Доступ: https://cr.minzdrav.gov.ru/view-cr/554_4 (дата обращения – 15.08.2026). [Clinical guidelines. Rectal cancer. Association of Coloproctologists of Russia, Association of Oncologists of Russia, Russian Society of Clinical Oncology, Russian Society of Colorectal Cancer Specialists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2025. ID: 554_4. URL: https://cr.minzdrav.gov.ru/view-cr/554_4 (date of access – 15.08.2026) (In Russ.)].
About the Authors
Elena I. Busalaeva, MD, PhD (Medicine), associate professor of the Department of therapy and general medical practice, Institute of Advanced Medical Training; associate professor of the Department of hospital therapy, I.N. Ulyanov Chuvash State University, Cheboksary, Russian Federation.E-mail: busa-elena@yandex.ru
ORCID: https://orcid.org/0000-0001-7313-0365. eLibrary SPIN: 1295-0473. AuthorID: 860185
Svetlana M. Zhuchkova, MD, PhD (Medicine), associate professor, head of the Department of clinical pharmacology, Republican Clinical Oncology Dispensary; associate professor of the Department of pharmacology, clinical pharmacology, and biochemistry, I.N. Ulyanov Chuvash State University; chief external specialist in clinical pharmacology of the Chuvash Republic; Cheboksary, Russian Federation.
E-mail: crista007@mail.ru
ORCID: https://orcid.org/0000-0002-2295-1363. eLibrary SPIN: 4277-2670. AuthorID: 647752
Galina A. Gromova, MD, clinical pharmacologist at Republican Oncology Dispensary, Petrozavodsk, Russian Federation.
E-mail: gaka-91@mail.ru
ORCID: https://orcid.org/0009-0008-2406-7767. eLibrary SPIN: 8412-6193. AuthorID: 1082979



